This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
本发明涉及新型2,3-二氢
咪唑[1,2-c]
喹唑啉化合物,含有这些化合物的药物组合物以及这些化合物或组合物用于
磷脂酰肌醇-3-激酶(
PI3K)抑制和治疗与
磷脂酰肌醇-3-激酶(
PI3K)活性相关的疾病,特别是治疗过度增殖和/或血管生成异常的疾病,作为唯一的药物或与其他活性成分联合使用。